Amyloidosis is a group of conditions in which misfolded proteins (amyloid fibrils) deposit in organs and tissues, causing progressive organ dysfunction. For walking and mobility, amyloidosis is relevant primarily through two routes: peripheral neuropathy (particularly in hereditary transthyretin amyloidosis, hATTR) and cardiac involvement (in both AL and hATTR amyloidosis), which limits exercise tolerance independently of limb function.
hATTR Amyloidosis: The Neuropathy Route
Hereditary transthyretin amyloidosis (hATTR, also called familial amyloid polyneuropathy or FAP) is caused by mutations in the TTR gene encoding transthyretin, a protein produced primarily in the liver. Mutant transthyretin misfolds and deposits in peripheral nerves, causing a length-dependent sensorimotor neuropathy that typically starts in the feet and ascends:
- Early stage: Reduced sensation in the feet and lower legs -- reduced proprioception, reduced pain and temperature sensation, tingling. Gait becomes less precise on uneven ground as proprioceptive feedback from the feet is lost
- Mid stage: Motor weakness begins to add to sensory loss -- foot weakness, reduced push-off, beginning of foot drop. A walking cane becomes clinically indicated in this phase
- Later stage: More extensive weakness and sensory loss ascending toward the knees, autonomic involvement (orthostatic hypotension -- see the autonomic neuropathy article), and increasing gait instability
Modern disease-modifying treatments (tafamidis, patisiran, inotersen, vutrisiran) can slow or halt neuropathy progression, but established nerve damage does not fully reverse. Walking aid use should progress with the clinical stage.
AL Amyloidosis and Walking
AL (light chain) amyloidosis results from plasma cell dyscrasia producing amyloidogenic immunoglobulin light chains that deposit in organs. AL most commonly affects the kidneys and heart. The cardiac involvement is most relevant to walking:
- Cardiac amyloidosis causes a restrictive cardiomyopathy -- the heart chambers stiffen, reducing the ability to increase cardiac output with exertion
- Exercise intolerance is an early feature -- patients feel breathless and fatigued with walking even before other symptoms are severe
- A walking cane in cardiac amyloidosis reduces the metabolic demand per step, helping patients maintain a degree of community ambulation within their cardiac output ceiling
- AL amyloidosis can also cause peripheral neuropathy, autonomic neuropathy, and musculoskeletal pain (shoulder pad sign, jaw claudication), all of which may contribute to gait impairment
Walking Cane Role by Amyloidosis Type and Stage
| Type/Stage | Primary Walking Limitation | Cane Role |
|---|---|---|
| hATTR -- early (sensory only) | Reduced proprioception, uneven terrain instability | Proprioceptive supplement, terrain safety |
| hATTR -- mid (sensory + motor) | Foot weakness, foot drop beginning | Structural gait support, foot drop compensation |
| hATTR -- late (severe neuropathy + autonomic) | Extensive weakness, orthostatic hypotension | Dual structural + postural support; walker may be needed |
| AL -- cardiac (restrictive cardiomyopathy) | Exercise intolerance, dyspnoea | Energy economy, extend walk range within cardiac ceiling |
| AL -- neuropathy component | Sensorimotor and autonomic neuropathy | As for hATTR stages above |
Explore the DaiWalk cane collection. Related: Walking Cane for Autonomic Neuropathy | Walking Cane for Peripheral Neuropathy
